Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a pioneering biopharmaceutical company dedicated to discovering and developing next-generation gene and cellular therapies in the United States. Specializing in disease-modifying therapeutics, Precigen has been at the forefront of genetic engineering and synthetic biology solutions. The company excels in creating innovative therapies for some of the most challenging diseases in areas such as immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen's core technologies include:
- UltraVector® Platform: This platform incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs.
- UltraCAR-T® Cell Therapies: These therapies address limitations of conventional CAR-T therapies by improving in vivo CAR-T expansion and persistence, adding safety features, and reducing manufacturing costs.
- AdenoVerse™ Technology Platform: A library of engineered adenovector serotypes, including gorilla adenovectors, which is used for gene delivery, and modulating immune responses.
- RheoSwitch® Inducible Gene Switch: This technology allows for precise control over gene expression, making therapies safer and more efficient.
Recent achievements include the Phase 2 pivotal study data for PRGN-2012 in treating recurrent respiratory papillomatosis (RRP), a rare and debilitating disease. The study showcased promising results, with 51% of patients achieving Complete Response, defined as no need for surgical interventions in the 12-month period following treatment.
Precigen is also actively developing UltraCAR-T therapies, which have demonstrated significant preliminary efficacy and safety advantages over existing CAR-T therapies. These therapies are currently being evaluated in clinical trials for various hematological and solid tumors.
Financially, Precigen has shown resilience, focusing on sound fiscal management while advancing its clinical pipeline. Despite experiencing fluctuations in research expenses and revenues, the company remains committed to achieving its milestones and maintaining a strong balance sheet.
Precigen's business model involves commercializing its technologies through collaborations with industry partners who possess specialized expertise, development resources, and sales capabilities. This collaborative approach enables Precigen to bring new and improved products to market efficiently.
For the latest updates on Precigen's innovative gene and cell therapies, visit their official website and follow them on social media platforms like X (formerly Twitter), LinkedIn, and YouTube.
Precigen, Inc. (Nasdaq: PGEN) reported a significant revenue increase of over 200% to $13.4 million for Q3 2022, driven by collaboration and licensing agreements. The company has retired $144 million of convertible notes, saving $5.4 million in interest. Ongoing clinical trials include PRGN-2012 for recurrent respiratory papillomatosis, and data will be showcased in January 2023. Cash reserves were reported at $153.8 million as of September 30, 2022. Precigen remains focused on its gene and cell therapy pipeline, indicating a substantial cash runway into Q4 2023.
Precigen, Inc. (Nasdaq: PGEN) will announce its third quarter 2022 financial results after market close on November 9, 2022. A conference call to discuss the results will be held at 4:30 PM ET on the same day. Participants can join by dialing 1-888-317-6003 (US), 1-866-284-3684 (Canada), or 1-412-317-6061 (International) with access code 3010378. Precigen focuses on gene and cell therapies, targeting diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen, Inc. (Nasdaq: PGEN) has appointed Rutul R. Shah as Chief Operating Officer (COO), effective October 1, 2022. Shah, who joined the company in 2014, will oversee strategic management of the company’s portfolio to enhance operational efficiency. With over 17 years in the biopharmaceutical industry, he brings significant expertise in gene and cell therapies. Precigen focuses on innovative treatments in immuno-oncology and other areas, aiming to advance its clinical pipeline. The company, led by President and CEO Helen Sabzevari, emphasizes a commitment to precision medicine.
Precigen, a biopharmaceutical company focused on gene and cell therapies, announced that its President and CEO, Helen Sabzevari, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts. The event is scheduled for September 7, 2022, at 11:35 AM ET. Precigen aims to improve patient lives through innovative therapies targeting urgent diseases, including areas like immuno-oncology and autoimmune disorders. More details regarding the conference can be found on their official website.
Precigen (Nasdaq: PGEN) announced the sale of its non-healthcare subsidiary, Trans Ova Genetics, for $170 million in upfront cash, plus an additional $10 million contingent on performance over the next two years. The proceeds will be utilized to pay senior convertible notes, aiming to enhance the company's financial position. This strategic move reflects Precigen's focus on its core operations in gene and cell therapies, enhancing shareholder value while streamlining its business portfolio.
Precigen (Nasdaq: PGEN) announced the completion of multiple Phase 1 clinical trials for its UltraCAR-T and AdenoVerse™ therapies, aimed at treating various cancers and conditions. A significant financial move includes the agreement to sell its subsidiary Trans Ova Genetics for $170 million, enhancing its balance sheet. As of June 30, 2022, Precigen reported cash reserves of $132.8 million. For the second quarter, total revenues fell 24%, leading to a loss from continuing operations of $26.1 million. However, the company remains optimistic, citing progress in key clinical programs and expected data presentations.
Precigen (Nasdaq: PGEN) will announce its second quarter and first half 2022 financial results after market close on August 8, 2022. A conference call is scheduled for 4:30 PM ET the same day to discuss these results and provide a business update. The company specializes in gene and cell therapies targeting immuno-oncology and other diseases. Precigen aims to innovate affordable biotherapeutics and advance its clinical pipeline.
Precigen has announced a definitive agreement to sell its non-healthcare subsidiary, Trans Ova Genetics, to URUS for $170 million in upfront cash, plus up to $10 million in earn-outs over two years. The sale aims to solidify Precigen's balance sheet, allowing payment of senior convertible notes due in July 2023. This divestiture aligns with Precigen's strategy to focus exclusively on healthcare, enhancing the development of its gene and cell therapies for serious diseases.
Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will join a virtual panel on June 30, 2022, at 1:00 PM ET during the Stifel 2022 Virtual Cell Therapy Summit. The discussion will focus on Targeted T Cell Therapies, including CAR T and TCR therapies. Precigen specializes in gene and cell therapies aimed at treating urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. More details about the event can be found on Precigen's website.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company, announced that Dr. Helen Sabzevari, President and CEO, will engage in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 AM ET. Interested participants can register for the webcast via Precigen's website. The company focuses on innovative gene and cell therapies targeting serious diseases, including immuno-oncology, autoimmune disorders, and infectious diseases. For more details, visit their official site.
FAQ
What is the current stock price of Precigen (PGEN)?
What is the market cap of Precigen (PGEN)?
What does Precigen, Inc. specialize in?
What are some of Precigen's core technologies?
What are the key areas of focus for Precigen's therapies?
What recent achievements has Precigen made?
How does Precigen commercialize its technologies?
What makes UltraCAR-T® Cell Therapies unique?
What is the AdenoVerse™ Technology Platform?
Where can I find more information about Precigen's latest updates?
What financial strategies does Precigen employ?
What is the RheoSwitch® Inducible Gene Switch?
